Association of HLA-A*02:01 type with efficacy and toxicity of immune checkpoint inhibitor therapy in melanoma patients: a retrospective cohort study
Abstract Background Immune checkpoint inhibitors (ICI) are highly effective but may induce severe or even fatal and unpredictable immune-related adverse events (irAEs). It is unclear whether human leukocyte antigen (HLA) genes contribute to the susceptibility of developing irAEs during ICI therapy....
Saved in:
| Main Authors: | Isabel Manger, Christina Schmitt, Carola Berking, Lars E. French, Julio Vera-Gonzalez, Lucie Heinzerling |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-03-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-13857-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Case of Hemophagocytic Lymphohistiocytosis During Immune Checkpoint Inhibitor Treatment for Metastatic Renal Cell Carcinoma, Complicated by Pancytopenia Attributed to Cytomegalovirus Infection
by: Tomoko Honda, et al.
Published: (2025-07-01) -
A review of immune checkpoint inhibitor-associated myocarditis: Epidemiology, pathogenesis, and biomarkers
by: Le Xu, et al.
Published: (2025-12-01) -
Evaluation of tumorous LCP1 and ADPGK as predictive biomarker for immune-related adverse events in bone and soft tissue sarcomas treated with anti-PD-1 and anti-PD-L1 antibodies
by: Qing Zhang, et al.
Published: (2025-04-01) -
Severe thyroiditis induced by sintilimab monotherapy in a patient with non-small cell lung cancer: a case report and literature review
by: Xiaolin Zhao, et al.
Published: (2025-02-01) -
Peripheral blood markers predict prognosis and irAEs of stage IV driver gene-negative lung adenocarcinoma treated with ICIs
by: Yu Li, et al.
Published: (2025-03-01)